– CANADA, Vancouver – NanoVation Therapeutics, a platform company developing innovative technologies to overcome barriers to nucleic acid delivery, announced the appointments of Dr. Zach Jonasson (Ph.D.) and David Main to its Board of Directors along with the close of a funding round led by Convergent Ventures.
About Dr. Zachariah Jonasson
Dr. Zach Jonasson is CFO and CBO of Absci Corp., a biotechnology company that uses generative AI at scale to create novel therapeutics. At Absci, he serves on the executive leadership team and is responsible for the company’s financial and business strategy. He is also a co-founder of two venture capital firms, Convergent Ventures and Phoenix Venture Partners, where he previously led each firm’s investment strategy in the biotechnology sector as a General Managing Partner.
About David Main
David Main has 30 years of biotechnology leadership experience. He is President and CEO of Notch Therapeutics, a company engineering pluripotent stem cells (iPSCs) to create a universal T cell. Previously, he was co-founder, Chairman, and CEO of Aquinox Pharmaceuticals and President and CEO of INEX Pharmaceuticals, a company developing lipid-based drug delivery systems for oncology therapeutics. Companies that spun out of INEX include Protiva Biotherapeutics and Tekmira, which was later rebranded as Arbutus Biopharma.
About NanoVation Therapeutics
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases.
For more information: https://nanovationtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.